N-acetylcysteine replenishes glutathione in HIV infection. 2000

S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
Department of Genetics, Stanford University, USA.

BACKGROUND Glutathione (GSH) deficiency is common in HIV-infected individuals and is associated with impaired T cell function and impaired survival. N-acetylcysteine (NAC) is used to replenish GSH that has been depleted by acetaminophen overdose. Studies here test oral administration of NAC for safe and effective GSH replenishment in HIV infection. METHODS Oral NAC administration in a randomized, 8-week double-blind, placebo-controlled trial followed by optional open-label drug for up to 24 weeks. METHODS HIV-infected, low GSH, CD4 T cells < 500 micro L(-1), no active opportunistic infections or other debilitation; n = 81. Study conducted prior to introduction of protease inhibitors. RESULTS Whole blood GSH levels in NAC arm subjects significantly increased from 0.88 mM to 0.98 mM, bringing GSH levels in NAC-treated subjects to 89% of uninfected controls (P = 0.03). Baseline GSH levels in the placebo group (0.91) remained essentially the same during the 8 week placebo-controlled trial. T cell GSH, adjusted for CD4 T cell count and beta2-microglobulin levels, also increased in the NAC-treated subjects (P = 0.04). Adverse effects were minimal and not significantly associated with NAC ingestion. CONCLUSIONS NAC treatment for 8 weeks safely replenishes whole blood GSH and T cell GSH in HIV-infected individuals. Thus, NAC offers useful adjunct therapy to increase protection against oxidative stress, improve immune system function and increase detoxification of acetaminophen and other drugs. These findings suggest that NAC therapy could be valuable in other clinical situations in which GSH deficiency or oxidative stress plays a role in disease pathology, e.g. rheumatoid arthritis, Parkinson's disease, hepatitis, liver cirrhosis, septic shock and diabetes.

UI MeSH Term Description Entries
D008297 Male Males
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000111 Acetylcysteine The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates. Mercapturic Acid,Acemuc,Acetabs,Acetylcystein AL,Acetylcystein Atid,Acetylcystein Heumann,Acetylcystein Trom,Acetylcysteine Hydrochloride,Acetylcysteine Sodium,Acetylcysteine Zinc,Acetylcysteine, (D)-Isomer,Acetylcysteine, (DL)-Isomer,Acetylcysteine, Monoammonium Salt,Acetylcysteine, Monosodium Salt,Acetylin,Acetyst,Acétylcystéine GNR,Airbron,Alveolex,Azubronchin,Bisolvon NAC,Bromuc,Broncho-Fips,Broncholysin,Broncoclar,Codotussyl,Cystamucil,Dampo Mucopect,Eurespiran,Exomuc,Fabrol,Fluimucil,Fluprowit,Frekatuss,Genac,Hoestil,Ilube,Jenacystein,Jenapharm,Lantamed,Larylin NAC,Lindocetyl,M-Pectil,Muciteran,Muco Sanigen,Mucomyst,Mucosil,Mucosol,Mucosolvin,N-Acetyl-L-cysteine,N-Acetylcysteine,NAC AL,NAC Zambon,Optipect Hustengetränk,Siccoral,Siran,Solmucol,acebraus,durabronchal,mentopin Acetylcystein,Acetylcystein, mentopin,Acid, Mercapturic,Broncho Fips,BronchoFips,Hustengetränk, Optipect,Hydrochloride, Acetylcysteine,M Pectil,MPectil,Monoammonium Salt Acetylcysteine,Monosodium Salt Acetylcysteine,Mucopect, Dampo,N Acetyl L cysteine,N Acetylcysteine,NAC, Bisolvon,Sanigen, Muco,Sodium, Acetylcysteine,Zambon, NAC,Zinc, Acetylcysteine
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
June 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
January 1997, Advances in pharmacology (San Diego, Calif.),
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
January 1992, American journal of hospital pharmacy,
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
February 2000, Immunology letters,
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
March 2000, Transplantation,
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
August 1992, AIDS (London, England),
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
May 2000, Chemical research in toxicology,
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
August 2007, Current opinion in pharmacology,
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
January 2018, Pakistan journal of pharmaceutical sciences,
S C De Rosa, and M D Zaretsky, and J G Dubs, and M Roederer, and M Anderson, and A Green, and D Mitra, and N Watanabe, and H Nakamura, and I Tjioe, and S C Deresinski, and W A Moore, and S W Ela, and D Parks, and L A Herzenberg, and L A Herzenberg
August 1997, Digestive diseases and sciences,
Copied contents to your clipboard!